Compositions for treating cystic fibrosis
AssigneeVertex Pharmaceuticals Incorporated
InventorsEleni Dokou, Briana Lauziere, Kirk A. Overhoff
Life of this patent
Estimating the term…
Abstract
A single tablet comprising Compound I. Methods of treating cystic fibrosis comprising administering one or more of such single tablets to a patient.
Claims79
A single tablet comprising a first solid dispersion, a second solid dispersion, and a third solid dispersion,
- (a) wherein the first solid dispersion comprises 50 mg to 300 mg of Compound I:
- and 10 wt % to 60 wt % of a polymer relative to the total weight of the first solid dispersion;
- (b) wherein the second solid dispersion comprises 10 mg to 50 mg of Compound II:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion;
- and
- (c) wherein the third solid dispersion comprises 25 mg to 200 mg of Compound III:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the third solid dispersion.
A single tablet comprising:
- (a) 20 wt % to 50 wt % of a first solid dispersion relative to the total weight of the tablet;
- (b) 10 wt % to 30 wt % of a second solid dispersion relative to the total weight of the tablet;
- and
- (c) 3 wt % to 10 wt % of a third solid dispersion relative to the total weight of the tablet;
- wherein the first solid dispersion comprises 40 wt % to 90 wt % of Compound I:
- and 10 wt % to 60 wt % of a polymer relative to the total weight of the first solid dispersion;
- wherein the second solid dispersion comprises 70 wt % to 90 wt % of Compound II:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion;
- and
- wherein the third solid dispersion comprises 70 wt % to 90 wt % of Compound III:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the third solid dispersion.
A single tablet comprising an intra-granular portion and an extra-granular portion, wherein either of the intra-granular portion or extra-granular position are comprised of a first solid dispersion comprising Compound I and a polymer, a second solid dispersion comprising Compound II and a polymer, and a third solid dispersion comprising Compound III and a polymer.
A method of treating cystic fibrosis in a patient comprising orally administering to the patient the single tablet of any one of claims 1-86.
Dependencies are inferred from the claim text.